November 24, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Redeye Life Science Day at 13:50 CET on November 26. The presentation will be livestreamed and can be followed at https://www.redeye.se/events/792760/redeye-life-science-day, where the presentation also will be available afterwards.

The presentation will also be available afterwards on the company’s page in Redeye Universe (www.redeye.se/company/index-pharmaceuticals) and on the company’s website (www.indexpharma.com).

 

For more information:

Peter Zerhouni, CEO
Phone: +46 8 122 038 50
E-mail: peter.zerhouni@indexpharma.com

 

InDex Pharmaceuticals in brief
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.

InDex is based in Stockholm, Sweden. The company’s shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm. Redeye AB with e-mail certifiedadviser@redeye.se and phone number +46 8 121 576 90 is the company’s Certified Adviser. For more information, please visit www.indexpharma.com.

Publication
The information was submitted for publication through the agency of the contact person set out above at 08:00 CET on November 24, 2020.